This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Invitrogen/Life Technologies (C): The "Best Owner" of the Asset
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209C-EStrategyThis short case discusses the process of Life Technologies’ acquisition by Thermo Fisher in 2013 and 2014. The case is a complement to SM-209A and SM-209B, which highlight the various growth and acquisition strategies the company undertook over the previous 10 years.Starting at €5.74
-
Applications for Financial Futures (Spanish version)
Mason, Scott P.; Durdan, Sally E.Case HBS-220S05FinanceConsists of a series of four brief descriptions of the use of financial futures as hedging vehicles: a savings and loan hedging the rollover of three-month money market certificates with T-bill futures, a corporate debt issuer hedging the cost of a future debt issue with T-bond futures, an equity investor hedging a decline in the market, and an example of a company with a natural interest rate hedge on its balance sheet. The examples describe the...Starting at €8.20
-
Basware in 2013: Transistion to Software as a Service
Burgelman, R; Schifrin, DCase SGSB-SM219-EStrategyIn 2013 Basware, the Finland-based e-invoice operator and Enterprise Resource Planning (ERP) software vendor, was going through a large and critical transition: moving from selling and installing licensed software to selling Software as a Service (SaaS). Basware, which sold automated Purchase-to-Pay solutions for Business-to-Business to 2,000 Nordic and global clients, was responding to a sharp decline in those sales in the previous few years; mo...Starting at €8.20
-
Axel Springer in 2016: From Transformation to Acceleration - Teaching Note
Burgelman, R; Siegel, R; Kissick, RTeaching Note SGSB-E610TN-EEntrepreneurshipAs of 2016, Mathias Döpfner, chief executive officer (CEO) of Axel Springer SE, had successfully transitioned the German publishing house through a major digital transformation in the world of journalism. Given the massive disruption that had occurred over the previous two decades with how people consumed news, this was no small feat. During this time, many newspapers, magazines, and journals failed to keep up with the rapidly changing industry...Starting at €0.00
-
Axel Springer in 2016: From Transformation to Acceleration
Burgelman, R; Siegel, R; Kissick, RCase SGSB-E610-EEntrepreneurshipAs of 2016, Mathias Döpfner, chief executive officer (CEO) of Axel Springer SE, had successfully transitioned the German publishing house through a major digital transformation in the world of journalism. Given the massive disruption that had occurred over the previous two decades with how people consumed news, this was no small feat. During this time, many newspapers, magazines, and journals failed to keep up with the rapidly changing industry...Starting at €8.20
-
Massey-Ferguson Ltd.--1980 (Spanish version)
Baldwin, Carliss Y.; Mason, Scott P.; Hughes, Jennifer H.Case HBS-202S12FinanceMassey Ferguson began fiscal year 1981 in default on $2.5 billion of outstanding debt. The company's future depends on the ability of lenders, the governments of Canada and Ontario, and management, to agree on a refinancing plan. The case reviews Massey's performance and position in the industry and raises questions about the company's ability to compete in the long run. Provides information on the firm's claimants in order to focus students on t...Starting at €8.20
-
Invitrogen (A)
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209A-EStrategyFounded in 1987, Invitrogen was one of the largest catalog life science companies in the industry. Its customers came from academic research, biotechnology and pharmaceutical companies and government laboratories. Scientists viewed Invitrogen as a one-stop shop for all major molecular biology, biochemistry and cell culture reagent products, with prices ranging from a hundred dollars to a few thousand dollars.Starting at €8.20
-
Invitrogen/Life Technologies (B)
Burgelman, R; Siegel, R; Lee, RCase SGSB-SM209B-EStrategyOn June 12, 2008, Invitrogen and Applied Biosystems announced plans to merge. The combined company was to be renamed Life Technologies (NASDAQ: LIFE). Invitrogen offered to acquire Applied Biosystems for $6.7 billion in cash and stock. AB shareholders would receive $38 per share in cash and stock, representing a 17 percent premium over the share’s closing price on Wednesday, June 11, 2008.Starting at €5.74
-
Waste Management's Organic Growth Group
Burgelman, R; Siegel, R; Uribe, TCase SGSB-SM210-EStrategyIt was 2005 and David Steiner, CEO of Waste Management (WM), had just received a report from an internal advisory panel created some months before to assess the future of the waste management industry and propose how the company’s strategy should be adapted. The core of this report was the recommendation to create a special unit within the company, chartered with the central purpose of identifying ways to extract value from waste through new and ...Starting at €8.20
-
DKSH in 2011
Burgelman, R; , Ludescher, MCase SGSB-SM204-EStrategyThe case describes the history and transformation of DKSH, a privately-held global trading company headquartered in Zurich, Switzerland, that has been doing business in the Far East for some 150 years. The case focuses on the efforts of CEO Joerg Wolle since 1999 to bring together several independent family-owned Swiss-based trading houses under one corporate roof and to transform successful but steady old-fashioned trading houses into a new type...Starting at €8.20